BioMarin Pharmaceutical/ US09061G1013 /
8/12/2022 9:59:59 PM | Chg. -0.07 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
95.04USD | -0.07% | 59,996 Turnover: 5.69 mill. |
-Bid Size: - | -Ask Size: - | 17.63 bill.USD | 0.00% | - |
Assets
2009 US GAAP in mill. USD |
2010 US GAAP in mill. USD |
2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Property and Equipment | 199.1000 | 221.9000 | 269 | 284.5000 | 319.3000 | ||||||
Intangible Assets | 41 | 103.6000 | 180.3000 | 163 | 163.1000 | ||||||
Long-Term Investments | - | - | - | - | - | ||||||
Fixed Assets | - | - | - | - | - | ||||||
Inventories | 78.7000 | 109.7000 | 130.1000 | 128.7000 | 162.6000 | ||||||
Accounts Receivable | - | - | - | - | - | ||||||
Cash and Cash Equivalents | 167.2000 | 88.1000 | 46.3000 | 180.5000 | 568.8000 | ||||||
Current Assets | 467.7000 | 504.3000 | 469.8000 | 743.5000 | 1,137.4000 | ||||||
Total Assets | 917.2000 | 1,262.6000 | 1,303.7000 | 1,601.6000 | 2,249.2000 |
Liabilities
2009 US GAAP in mill. USD |
2010 US GAAP in mill. USD |
2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Accounts Payable | 78.1000 | 83.6000 | 0.0000 | 0.0000 | 0.0000 | ||||||
Long-term debt | - | - | - | - | - | ||||||
Liabilities to Banks | 0.0000 | 0.0000 | 0.0000 | 23.4000 | 0.0000 | ||||||
Provisions | - | - | - | 33.3000 | - | ||||||
Liabilities | 595 | 545.4000 | 530.6000 | 585.9000 | 908.2000 | ||||||
Share Capital | - | - | - | - | - | ||||||
Total Equity | 322.2000 | 717.3000 | 773 | 1,015.8000 | 1,341 | ||||||
Minority Interests | - | - | - | - | - | ||||||
Total liabilities equity | 917.2000 | 1,262.6000 | 1,303.7000 | 1,601.6000 | 2,249.2000 |
Income Statement
2009 US GAAP in mill. USD |
2010 US GAAP in mill. USD |
2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 324.7000 | 376.3000 | 441.4000 | 500.7000 | 548.5000 | ||||||
Depreciation (total) | 2.9000 | 6.4000 | 1.4000 | 18.7000 | 18.6000 | ||||||
Operating Result | 16.4000 | .5000 | -33.9000 | -110.2000 | -156 | ||||||
Interest Income | -9 | -6.2000 | -5.4000 | -5 | -7.3000 | ||||||
Income Before Taxes | .6000 | -21.5000 | -43.6000 | -118.3000 | -176.5000 | ||||||
Income Taxes | 1.1000 | -227.3000 | 10.2000 | -3.9000 | -.2000 | ||||||
Minority Interests Profit | - | - | - | - | - | ||||||
Net Income | -.5000 | 205.8000 | -53.8000 | -114.3000 | -176.4000 |
Per Share
Cash Flow
2009 US GAAP in mill. USD |
2010 US GAAP in mill. USD |
2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flow from Operating Activities | 87.7000 | 18.7000 | 18.8000 | 17.6000 | -59.6000 | ||||||
Cash Flow from Investing Activities | -79.7000 | -101.3000 | -89.6000 | -195.6000 | -298.8000 | ||||||
Cash Flow from Financing | -63.8000 | 3.5000 | 29 | 312.3000 | 746.7000 | ||||||
Decrease / Increase in Cash | -55.7000 | -79.1000 | -41.8000 | 134.3000 | 388.3000 | ||||||
Employees | 720 | 871 | 1,002 | 1,089 | 1,341 |